about
Microsomal prostaglandin E synthase-1 promotes hepatocarcinogenesis through activation of a novel EGR1/β-catenin signaling axisProstaglandin Gbetagamma signaling stimulates gastrulation movements by limiting cell adhesion through Snai1a stabilization.Hypoxia-inducible factor-1 alpha, in association with inflammation, angiogenesis and MYC, is a critical prognostic factor in patients with HCC after surgery.COX-2 in liver, from regeneration to hepatocarcinogenesis: what we have learned from animal models?miR-21 targets 15-PGDH and promotes cholangiocarcinoma growth.A hepatoprotective Lindera obtusiloba extract suppresses growth and attenuates insulin like growth factor-1 receptor signaling and NF-kappaB activity in human liver cancer cell lines.Cytosolic phospholipase A2alpha and peroxisome proliferator-activated receptor gamma signaling pathway counteracts transforming growth factor beta-mediated inhibition of primary and transformed hepatocyte growthCorrelation of microRNA-16, microRNA-21 and microRNA-101 expression with cyclooxygenase-2 expression and angiogenic factors in cirrhotic and noncirrhotic human hepatocellular carcinomaGene systems network inferred from expression profiles in hepatocellular carcinogenesis by graphical Gaussian model.Cytosolic phospholipase A(2)α protects against Fas- but not LPS-induced liver injury.Anti-Inflammatory and Analgesic Effects of the Marine-Derived Compound Excavatolide B Isolated from the Culture-Type Formosan Gorgonian Briareum excavatum.Tumor secretion of VEGF induces endothelial cells to suppress T cell functions through the production of PGE2.Elevation of ω-3 Polyunsaturated Fatty Acids Attenuates PTEN-deficiency Induced Endometrial Cancer Development through Regulation of COX-2 and PGE2 ProductionCyclooxygenase-2 and vascular endothelial growth factor in chronic hepatitis, cirrhosis and hepatocellular carcinoma.Prevention of hepatocellular adenoma and correction of metabolic abnormalities in murine glycogen storage disease type Ia by gene therapy.Octreotide and celecoxib synergistically encapsulate VX2 hepatic allografts following transcatheter arterial embolisationGenomic profiling reveals an alternate mechanism for hepatic tumor promotion by perfluorooctanoic acid in rainbow trout.PPARalpha- and DEHP-Induced CancersTissue metabolomics of hepatocellular carcinoma: tumor energy metabolism and the role of transcriptomic classification.Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma.Microsomal prostaglandin E synthase-1 protects against Fas-induced liver injury.Cyclooxygenase-2 induced β1-integrin expression in NSCLC and promoted cell invasion via the EP1/MAPK/E2F-1/FoxC2 signal pathway.Cyclooxygenase-2 prevents fas-induced liver injury through up-regulation of epidermal growth factor receptor.Omega-3 polyunsaturated fatty acids inhibit hepatocellular carcinoma cell growth through blocking beta-catenin and cyclooxygenase-2.The epidermal growth factor receptor: a link between inflammation and liver cancer.15-PGDH inhibits hepatocellular carcinoma growth through 15-keto-PGE2/PPARγ-mediated activation of p21WAF1/Cip1.Prostaglandin E2 stimulates β1-integrin expression in hepatocellular carcinoma through the EP1 receptor/PKC/NF-κB pathway.Epidermal Growth Factor Receptor (EGFR) Crosstalks in Liver Cancer.The effects of reactive species on the tumorigenic phenotype of human head and neck squamous cell carcinoma (HNSCC) cells.Prostaglandin E2 accelerates invasion by upregulating Snail in hepatocellular carcinoma cells.Enhanced 5-fluorouracil cytotoxicity in high COX-2 expressing hepatocellular carcinoma cells by wogonin via the PI3K/Akt pathway.Synthesis and characterization of celecoxib derivatives as possible anti-inflammatory, analgesic, antioxidant, anticancer and anti-HCV agents.Total saponin from root of Actinidia valvata Dunn prevents the metastasis of human hepatocellular carcinoma cells.Quercetin attenuates TNF-induced inflammation in hepatic cells by inhibiting the NF-κB pathway.Dual action of a selective cyclooxygenase-2 inhibitor on vascular endothelial growth factor expression in human hepatocellular carcinoma cells: novel involvement of discoidin domain receptor 2.Inhibitory effect of celecoxib in lung carcinoma by regulation of cyclooxygenase-2/cytosolic phospholipase A₂ and peroxisome proliferator-activated receptor gamma.The inhibitory effect of celecoxib on mouse hepatoma H22 cell line on the arachidonic acid metabolic pathway.Adjuvant celecoxib and lanreotide following transarterial chemoembolisation for unresectable hepatocellular carcinoma: a randomized pilot study.Metabolomics and eicosanoid analysis identified serum biomarkers for distinguishing hepatocellular carcinoma from hepatitis B virus-related cirrhosis.Brain fatty acid-binding protein and omega-3/omega-6 fatty acids: mechanistic insight into malignant glioma cell migration.
P2860
Q24312971-B6BDFB28-EBB5-4C85-9884-1F172530D91FQ30493925-6E0312E8-7CFA-4E3B-A02B-6887B83ACE4FQ30932207-9CC1461B-0B4A-446B-8C8B-EB202D925B89Q33756224-A0F694CE-570C-40B4-A36D-B08F65CA9769Q33758343-C778FDB6-9F16-4D4E-94CB-62D7658FDE3DQ33898852-80597877-5C8F-47BE-80A1-1BF7CC342299Q34455310-A65FDF92-37FF-4A2B-A59C-33EAE232A3C1Q35156115-A79ECB8C-07E6-4EFA-B3C6-9827C59FE729Q35208942-4569D23F-D11A-4B89-AD72-0B9EA2ACB69EQ35566362-74A1B7AF-A76A-411A-A09E-E67EF28E66D0Q35617492-A9E42048-C7CB-4DF3-9FF2-02C790802324Q35906001-61F8319F-7EC6-4A83-9768-D44A30D96EDAQ36163869-5CEED799-46D4-4233-9188-E3476BC9F47BQ36306698-633E50F1-D01D-4815-9ABF-876D9A55BBDFQ36336550-485B95A2-9E7A-49D8-BCAD-87F2144786F0Q36603626-F1D8FEAA-BF21-4389-A3B2-F9005973BF3DQ36838204-FD6E9738-D392-4225-B126-396770916673Q36857053-A6E4E8C0-6880-46EF-A9DE-9882D5425FBFQ36961679-B160EE0A-F908-4C2A-BD76-CB605AA3EE1AQ37036925-112BDD2E-2CED-4EE1-81B2-1B560CF0C755Q37071815-B3D97EE3-786B-4A09-A54D-CB62B2377D9EQ37274028-42A50A16-B636-482E-B28C-BA2ABDC80090Q37378968-064BEDC8-0081-4B32-B435-25FE606F6ECCQ37438352-A719A31F-D3CE-4D85-A526-CB9DD4AEF596Q37476452-E7D762F7-A1D0-4E75-8E6B-935F247A1F99Q37549404-C652AB82-C72E-4391-AD28-7A14FA065655Q37734894-ED506F68-CBE7-4661-84CF-F0D4DF40DF18Q38161361-D3E9BD0F-FCD3-45A5-91CD-3278622EA728Q38778874-C0A63D35-353D-49A6-B1E4-F9D1C02587A8Q39001620-0FB1D289-4383-4B8A-98A7-6B58F4D753CDQ39125279-3172CD19-6845-4D72-9200-B1085513AA9DQ39177383-F4ED57C3-D210-47C4-990B-1794A8D44A7CQ39371001-BF71328A-AD81-4CA0-8E03-AC15F046D98EQ39373161-DDAFE379-88C8-45DA-A41B-C3E98A2C6094Q39456277-4FA86C70-34B2-43F6-85BB-AC10DF193133Q39544858-90CFAC8A-33AE-40C5-8C96-531B2296A1F8Q39677057-2CD5875B-E233-46EE-A3E9-9344D6225E2CQ41471591-9ED759C5-19E9-4B24-83EA-E4B7BF4421B9Q41926352-B698ED42-24F7-47C4-B4BE-7482D617423DQ41984462-24C76FB8-6BAE-421E-8398-89311D14299E
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Cyclooxygenase-2 in hepatocellular carcinoma.
@ast
Cyclooxygenase-2 in hepatocellular carcinoma.
@en
type
label
Cyclooxygenase-2 in hepatocellular carcinoma.
@ast
Cyclooxygenase-2 in hepatocellular carcinoma.
@en
prefLabel
Cyclooxygenase-2 in hepatocellular carcinoma.
@ast
Cyclooxygenase-2 in hepatocellular carcinoma.
@en
P1476
Cyclooxygenase-2 in hepatocellular carcinoma.
@en
P2093
P356
10.1016/J.CTRV.2005.10.004
P577
2005-12-07T00:00:00Z